SA PRO
Free Account
Themes
Bio-Techne CorporationTECHNASDAQ
Loading
OverviewIntelligenceChartsNews

Analyst Sentiment

Analysts lean bullish — 78% recommend buying.

Consensus Rating
Buy
23 analysts·High coverage
78%
Rating Distribution
Strong Buy
00%
Buy
1878%
Hold
522%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 21% higher.

Bear Case
$62.00
+8%
Consensus
$69.33
+21%
Bull Case
$79.00
+38%
Price Range23 analysts
Low
Consensus
High
$62.00
$79.00
Current Target
Current Price
$57.26
Upside to Target
$12.07

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Feb 5, 2026Stifel Nicolaus
Bio-Techne price target raised to $65 from $60 at Stifel
Target:$65.00
-3.9%from $67.64
Feb 5, 2026UBS
Bio-Techne price target raised to $79 from $70 at UBS
Target:$79.00
+15.0%from $68.67
Feb 5, 2026Robert W. Baird
Bio-Techne price target raised to $70 from $61 at Baird
Target:$70.00
+1.9%from $68.67
Jan 5, 2026Evercore ISI
Bio-Techne downgraded to In Line from Outperform at Evercore ISI
Target:$62.00
+3.9%from $59.65
Dec 12, 2025Deutsche Bank
Bio-Techne price target raised to $72 from $66 at Deutsche Bank
Target:$72.00
+20.7%from $59.67
Nov 20, 2025Argus Research
Bio-Techne price target raised to $68 from $65 at Argus
Target:$68.00
+16.0%from $58.64
Nov 6, 2025Evercore ISI
Bio-Techne price target lowered to $68 from $72 at Evercore ISI
Target:$68.00
+16.4%from $58.40
Sep 2, 2025RBC Capital
Bio-Techne upgraded to Outperform at RBC on forecast multiple expansion
Target:$73.00
+36.7%from $53.42
Mar 17, 2025Evercore ISI
Bio-Techne initiated with an Outperform at Evercore ISI
Target:$75.00
+19.8%from $62.58
Oct 31, 2024Robert W. Baird
Bio-Techne Corp. (TECH) PT Raised to $84 at Baird
Target:$84.00
+10.5%from $76.02
Oct 30, 2024KeyBanc
KeyBanc Reiterates Overweight Rating on Bio-Techne Corp. (TECH)
Target:$80.00
+5.2%from $76.02
Aug 16, 2024Scotiabank
Scotiabank Reiterates Sector Outperform Rating on Bio-Techne Corp. (TECH)
Target:$83.00
+11.9%from $74.19
Dec 14, 2022Deutsche Bank
Deutsche Bank Initiates Coverage On Bio-Techne with Buy Rating, Announces Price Target of $100
Target:$100.00
+15.0%from $86.98
Dec 12, 2022Citigroup
Citigroup Upgrades Bio-Techne to Buy, Raises Price Target to $100
Target:$100.00
+23.9%from $80.73
Dec 7, 2022RBC Capital
RBC Capital Initiates Coverage On Bio-Techne with Sector Perform Rating, Announces Price Target of $89
Target:$89.00
+10.3%from $80.67
Dec 5, 2022Stephens
Stephens & Co. Maintains Overweight on Bio-Techne, Adjusts Price Target to $105 - 4-for-1 Stock Split
Target:$105.00
+27.4%from $82.44
May 5, 2022KeyBanc
Bio-Techne (TECH) Stock: $500 Price Target And Overweight Rating
Target:$500.00
+405.3%from $98.96
Apr 25, 2022Wells Fargo
Wells Fargo Downgrades Bio-Techne to Underweight, Lowers Price Target to $370
Target:$370.00
+267.3%from $100.75
May 6, 2021Citigroup
Bio-Techne Corp. (TECH) PT Raised to $425 at Citi
Target:$425.00
+314.8%from $102.45

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance